Finch throws in the tow­el on mi­cro­bio­me jour­ney, lets go of 77 em­ploy­ees

Finch Ther­a­peu­tics’ at­tempt to make crap­sules that help pre­vent the re­cur­rence of a bac­te­r­i­al in­fec­tion is near­ing the end of the road.

For the third time in nine months, the Boston-area biotech will lay off staffers, this time 95%, which equates to 77 em­ploy­ees.

As is be­com­ing more and more fa­mil­iar in biotech these days, Finch flashed red lights ear­ly Tues­day, say­ing it will scrap a Phase III tri­al test­ing its donor stool-in-a-cap­sule for the pre­ven­tion of re­cur­ring in­fec­tion from the bac­te­ria Clostrid­ioides dif­fi­cile, or C. diff.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA